Priyantha Ranaweera, MD
Interventional Cardiology · Manhattan, KSNPI 1497952998
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (37.7%), other and travel and lodging — rather than concentrated in one kind of arrangement. 43 manufacturers reported payments, led by Angiodynamics, Inc. at 38.3% of the total. 2025 is the largest year on record at $16,021, 4.5 times the $3,537 reported in 2019. Among interventional cardiology clinicians in KS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 665 payments — averaging $62.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$16K
- Abbott$14K
- Bard Peripheral Vascular, Inc.$2K
- Medtronic$2K
- Pfizer$849
- Novartis$633
- plus $6K from 37 others
What the payments were for
- Travel & lodging$10,13325%
- Food & beverage$15,58738%
- Education$6071%
- Other$15,00036%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auryon Laser System 100-120 Vac$15,535
- PERCLOSE PROGLIDE$3,519
- CARDIOMEMS$2,041
- OMNILINK ELITE$1,611
- Perclose ProStyle$1,315
- OPTIS$1,242
- SUPERA$775
- Torus Stent Graft System$502
- ENDOCROSS Device$502
- ESPRIT$398
- Micra$238
- Abre$119
- JETi Peripheral Catheter$115
- Diamondback Peripheral$114
- COBALT DR MRI SURESCAN$105
How this compares
$41,327 in reported general payments places this provider in the 90th percentile of 55 interventional cardiology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 398 | $362,071 |
| EntrestoSacubitril/Valsartan | 352 | $306,894 |
| JardianceEmpagliflozin | 193 | $154,099 |
| FarxigaDapagliflozin Propanediol | 174 | $153,293 |
| XareltoRivaroxaban | 161 | $142,187 |
| Repatha SureclickEvolocumab | 72 | $58,102 |
| VerquvoVericiguat | 56 | $49,195 |
| BrilintaTicagrelor | 38 | $29,856 |
| MultaqDronedarone Hcl | 21 | $19,165 |
| Ranolazine ErRanolazine | 152 | $14,142 |
| Metoprolol Succinate | 738 | $9,164 |
| Nicardipine Hcl | 20 | $8,968 |
| Dofetilide | 43 | $8,320 |
| Praluent PenAlirocumab | 15 | $7,484 |
| ClopidogrelClopidogrel Bisulfate | 648 | $4,966 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $849 | $362,071398 claims |
| NovartisEntresto | $633 | $306,894352 claims |
| AstraZenecaFarxiga, Brilinta | $402 | $183,149212 claims |
| Boehringer IngelheimJardiance | $481 | $154,099193 claims |
| Johnson & JohnsonXarelto | $250 | $142,187161 claims |
| MerckVerquvo | $352 | $49,19556 claims |
| Sanofi-aventis U.S. LLCMultaq | $328 | $19,16521 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 55 interventional cardiology providers in Kansas.
Other interventional cardiology in Manhattan
- Ramez SmairatManhattan$11K
- William FreundManhattan$947
- Anthony SpaedyKansas City$385K
- Prasad GunasekaranKansas City$76K
- Maheedhar GedelaWichita$54K
- Kamal GuptaKansas City$46K
- Mark WileyKansas City$39K
- Ahmed SoukaTopeka$37K
- Pouyan ArmanOverland Park$33K
- John SerfasKansas City$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.